Take This Into Account Before Investing in Grifols (GRFS)

Grifols logged a 7.0% change during today's afternoon session, and is now trading at a price of $8.61 per share. The S&P 500 index moved 1.8%. GRFS's trading volume is 864,343 compared to the stock's average volume of 1,369,393.

Grifols trades -22.62% away from its average analyst target price of $11.12 per share. The 2 analysts following the stock have set target prices ranging from $9.18 to $13.05, and on average have given Grifols a rating of hold.

If you are considering an investment in GRFS, you'll want to know the following:

  • Grifols's current price is 153.3% above its Graham number of $3.4, which implies that at its current valuation it does not offer a margin of safety

  • Grifols has moved -29.3% over the last year, and the S&P 500 logged a change of -20.8%

  • Based on its trailing earning per share of 0.11, Grifols has a trailing 12 month Price to Earnings (P/E) ratio of 78.2 while the S&P 500 average is 15.97

  • GRFS has a forward P/E ratio of 16.9 based on its forward 12 month price to earnings (Eps) of $0.51 per share

  • Its Price to Book (P/B) ratio is 1.8 compared to its sector average of 4.07

  • Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives.

  • Based in Barcelona, the company has 27,584 full time employees and a market cap of $7,348,540,928.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.